Clinical Trial Search

Primary: Headache Severity as Measured on an 11-point Verbal Scale (0 to 10):0=No Pain 10=Excruciating Pain — -3.29; -3.70 units on a scale — p=<0.01

Primary: Length of Hospital Stay — 23.2; 30.8 hours

Primary: Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger — 36; 49; 98; 117 participants — p=0.026

Primary: Number of Participants Scored as Responder in Maintenance Phase. — 65; 75; 55 participants

Primary: Change From Baseline at Month 1 in Central Subfield Thickness (CSFT) as Measured by Spectral Domain Ocular Coherence Tomography (SD-OCT) — -142.3; -181.6; -175.6; -174.9…

Primary: Number of Participants Who Achieved > or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF. — 15 participants

Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml

Primary: Overall Survival — 14.9; 11.3 Months — p=0.00005

Primary: Change in Triglyceride Level — -52; -16 mg/dL

Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline

Primary: Duration of Admission at the Ward in Days — 9; 8 number of days — p=<0.05

Primary: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. — 39.5; 21.65 Percent…

Primary: Composite Success Based Upon Harris Hip Score, Radiographic and Survivorship Outcomes — 82; 92 participants — p=0.872

Primary: Progression-free Survival (PFS) of Participants Who Received RAD001 Plus Bevacizumab Versus Participants Who Received IFN Plus Bevacizumab — 9.3; 10.0 Months

Primary: Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups — 1.5; -0.5; 2.0; -1.0 percentage of change in…